In addition, MD001 showed no severe adverse effects such as fatty liver, body weight gain, liver toxicity, and hepatomegaly commonly observed with previous PPAR agonists, thereby alleviating metabolic disorders. This evidence concerns the gene PPARA and Other metabolic disease.